Combination Chemotherapy With Doxorubicin and Lomustine: Treatment of Refractory Hodgkin's Disease

Stephen D. Williams, Lawrence H. Einhorn

Research output: Contribution to journalArticle

10 Scopus citations


Ten patients with advanced Hodgkin's disease refractory to combination therapy with nitrogen mustard, vincristine sulfate, procarbazine, and prednisone (MOPP) were treated with a combination of doxorubicin hydrochloride and lomustine. Toxicity was acceptable. Five patients (50%) attained complete remission (median duration, 15 months). Three patients attained a partial remission (median duration, four months). Survival ranged from three to more than 40 months, and five patients are still alive. One patient remains disease-free after a course of radiation therapy to a site of localized nodal relapse. The doxorubicin-lomustine regimen has induced meaningful remissions in a patient population with very refractory disease.

Original languageEnglish (US)
Pages (from-to)1659-1661
Number of pages3
JournalJAMA: The Journal of the American Medical Association
Issue number15
StatePublished - Oct 10 1977


ASJC Scopus subject areas

  • Medicine(all)

Cite this